Vimarsana
Biggest News Aggregation in the World

Page 13 - Merck Sharp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Merck Sharp Today - Breaking & Trending Today

Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC - Vimarsana News

Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC

Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.

NGM Biopharmaceuticals (NASDAQ:NGM) and AgeX Therapeutics (NYSE:AGE) Financial Review - Vimarsana News

NGM Biopharmaceuticals (NASDAQ:NGM) and AgeX Therapeutics (NYSE:AGE) Financial Review

NGM Biopharmaceuticals (NASDAQ:NGM – Get Free Report) and AgeX Therapeutics (NYSE:AGE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership. Volatility and Risk NGM Biopharmaceuticals has a […]

20 Biggest Health Care Companies in Australia, 2024 - Vimarsana News

20 Biggest Health Care Companies in Australia, 2024

In this article, we will be taking a look at the 20 biggest health care companies in Australia, 2024.

Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC - Vimarsana News

Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC

Pembrolizumab in combination with chemotherapy followed by maintenance olaparib did not meet its pre-specified statistical criteria of overall survival or progression free survival.

Head-To-Head Comparison: AgeX Therapeutics (NYSE:AGE) and NGM Biopharmaceuticals (NASDAQ:NGM) - Vimarsana News

Head-To-Head Comparison: AgeX Therapeutics (NYSE:AGE) and NGM Biopharmaceuticals (NASDAQ:NGM)

NGM Biopharmaceuticals (NASDAQ:NGM – Get Free Report) and AgeX Therapeutics (NYSE:AGE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Volatility & Risk NGM Biopharmaceuticals has a […]